Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
Ryan Allway August 23rd, 2022 Psychedelics, Top News Based on over 20 years of pioneering Yale University research, clinical development currently underway to create and develop viable and efficacious treatment alternatives for patients with major depressive disorder by leveraging the known pharmacology of ketamine and psychedelic-based therapeutics SAN FRANCISCO, August... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )